Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.43 |
| ▸ | HTR1A | P08908 | 6/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9792617 | 0.86 | GAA (0.41) | GRIN1GRIN2AADRA1AADRA1BHTR1A | |
| SCHEMBL11696440 | 0.84 | GRIN1 (0.40) | GRIN1GRIN2AADRA1AADRA1BHTR1A | |
| Iodomethane SCHEMBL9792638 | 0.83 | GAA (0.40) | GRIN1GRIN2AADRA1AADRA1BHTR1A | |
| SCHEMBL9792578 | 0.82 | ADRA1A (0.37) | GRIN1GRIN2AADRA1AADRA1BHTR1A | |
| SCHEMBL9698509 | 0.81 | ESR2 (0.42) | GRIN1GRIN2AADRA1AADRA1B | |
| SCHEMBL750050 | 0.80 | ADRA1A (0.37) | GRIN1GRIN2AADRA1AADRA1BHTR1A | |
| SCHEMBL14039677 | 0.79 | GRIN1 (0.45) | GRIN1GRIN2AADRA1AADRA1BHTR1A | |
| SCHEMBL10816606 | 0.79 | GRIN1 (0.41) | GRIN1GRIN2AADRA1AADRA1BHTR1A | |
| SCHEMBL10875203 | 0.79 | GRIN1 (0.36) | GRIN1GRIN2AADRA1AADRA1BHTR1A | |
| SCHEMBL5156026 | 0.78 | CHRNB2 (0.40) | ADRA1AADRA1BHTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0194906-B1 | HETEROCYCLIC DISSYMMETRIC 1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC-ACID ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | FOURNIER INNOVATION ET SYNERGIE (FR) | 1989-07-19 | — | — | EP | claimed |
| WO-2014094961-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-06-26 | — | — | WO | disclosed |
| US-8030368-B2 | Photoinitiated reactions | LINTFIELD LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070185225-A1 | Photoinitiated reactions | LINTFIELD LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | GRIN1 276/4885GRIN2A 330/4885ADRA1A 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.